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Abstract 
The use of vaccines based on MUC1 glycopeptides is a promising approach to treat cancer. We 
present herein several sulfa-Tn antigens incorporated in MUC1 sequences that possess a variable 
linker between the carbohydrate (GalNAc) and the peptide backbone. The main conformations of 
these molecules in solution have been evaluated by combining NMR experiments and molecular 
dynamics simulations. The linker plays a key role in the modulation of the conformation of these 
compounds at different levels, blocking a direct contact between the sugar moiety and the 
backbone, promoting a helix-like conformation for the glycosylated residue and favoring the proper 
presentation of the sugar unit for molecular recognition events. The feasibility of these novel 
compounds as mimics of MUC1 antigens has been validated by X-ray diffraction structure of one of 
these unnatural derivatives complexed to an anti-MUC1 monoclonal antibody. These features, 
together with potential lack of immune suppression, render these unnatural glycopeptides promising 
candidates for designing alternative therapeutic vaccines against cancer. 
Introduction 
Chemistry-based approaches are of paramount importance to battle disease. In the quest of chemical 
weapons against cancer, MUC1 is a glycoprotein over-expressed in most of tumors.1-4 While in 
healthy cells, the MUC1 backbone presents complex oligosaccharides, in tumor cells the peptide 
backbone is decorated with simple and truncated carbohydrates. As a consequence, different tumor-
associated carbohydrate antigens (TACAs), such as the Tn determinant (α-O-GalNAc-Ser/Thr),5 are 
exposed to the immune system and can be recognized by different antibodies.6 For this reason, 
MUC1 derivatives are attracting great interest as a potential tool in developing therapeutic vaccines 
for the treatment of cancer.4,7,8 However, to date, none of these vaccines have succeeded in clinical 
trials.9 On the one hand, natural TACAs are tolerated by the immune system.10 To overcome this 
problem, chemical modifications of these antigens, generating non-natural determinants have been 
proposed.7,11-20 On the other hand, most glycan antigens are B-cell epitopes and produce only short-
Page 2 of 38
ACS Paragon Plus Environment
The Journal of Organic Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 3
lived and low-affinity antibodies.4 Induction of a robust immune response that produces high 
affinity IgG antibodies is essential and may be achieved through initiation of a T-cell-dependent 
pathway. 
 
 
 
 
 
 
 
 
 
Figure 1. (a) Crystal structure of a MHC-I molecule in complex with a glycopeptide containing a 
linker between the peptide backbone and the sugar moiety (PDB id: 1KBG, ref. 21e). (b) Design of 
novel glycopeptides containing a linker that favors the presentation of the sugar moiety and 
facilitates the interaction with T-cell receptors. (d) General structure of the neoglycopeptides 
synthesized and studied in this work. The peptide sequence PDTRP constitutes the most 
immunogenic domain of mucin MUC1.6 
 
A key step in this process is the presentation of the antigen through the major histocompatibility 
(MHC) molecule to T-cell receptors. In that context, recent studies indicate that glycopeptides can 
arbitrate classical MHC-mediated immune response.21 The crystal structure of an MHC-I molecule 
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with a glycopeptide containing a linker between the peptide and the sugar21e showed that while the 
aglycone part of the antigen binds to MHC molecule, the carbohydrate moiety can facilitate the 
recognition of T cell receptors (TCR) and therefore can stimulate immune response (Figures 1a and 
1b). 
In an effort to combine these two concepts, we present herein a set of unnatural Tn antigens 
characterized by the incorporation of a flexible and variable linker in their structures, placed 
between a peptide fragment and the GalNAc moiety (Figure 1c).  These new sulfa-Tn derivatives 
have been prepared as Fmoc-protected glycosyl amino acids, ready to use in solid phase peptide 
synthesis (SPPS). They have been included in the Ala-Pro-Asp-Xaa(α-S-GalNAc)-Arg-Pro peptide 
sequence, which constitutes the key immunogenic epitope of MUC16 when Xaa is a threonine. In 
particular, in this work, we have synthesized and studied six neoglycopeptides, being Xaa a 
cysteine, homocysteine, homohomocysteine, O-(mercaptopropyl)serine, S-
(mercaptopropyl)cysteine, or O-(mercaptopropyl)threonine residue. The main conformations of 
these molecules in solution have been evaluated. The linker plays a key role in the conformational 
behavior of these molecules, from the global 3D structure to the presentation of the glycan part of 
these compounds. Indeed, the linker blocks the direct contact between the sugar moiety and the 
backbone, promotes a helix-like conformation for the glycosylated residue, provides extra 
flexibility to the molecule and favors the presentation of the sugar unit for molecular recognition 
events. These novel compounds are indeed mimics of MUC1 antigens as demonstrated by the 
analysis of the X-ray diffraction data obtained for one of these unnatural glycopeptides complexed 
to an anti-MUC1 monoclonal antibody. The global behavior of this complex has also been analyzed 
by MD simulations. 
Results and Discussion 
From a synthetic perspective, the existence of S-glycopeptides with important biological properties 
has stimulated the development of a variety of glycosylation methods. These methods generally use 
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protected carbohydrates as electrophiles and Cys derivatives as nucleophiles. Alternatively, 
dehydroalanine (Dha)22-24 containing peptides and nucleophilic thiocarbohydrate derivatives25 have 
been used in 1,4-conjugate additions with poor results in diastereoselectivity.26 Recently, we have 
reported a new chiral Dha derivative,27 which has been used as acceptor in stereoselective sulfa-
Michael additions of appropriately protected thiocarbohydrates. This procedure has been applied to 
the synthesis of S-(2-acetamido-2-deoxy-α-D-galactopyranosyl)-L-cysteine, which could be 
considered as a mimic of the Tn antigen.28 A method based on the alkene hydrothiolation reaction,29 
which is called thiol–ene coupling (TEC), has also been developed. The thermally or 
photochemically induced TEC versions occur through a radical mechanism in anti-Markovnikov 
regioselective fashion.29 These methods have been applied, in general, to the synthesis of β-S-
glycosyl amino acids and β-S-glycopeptides.29 Nevertheless, the α-S-glycosidic bond formation in 
these motifs,29c especially the α-S-GalNAc moiety of the Tn antigen,30,31 has received little 
attention. In that context, the synthesis of α-thio-linked glycosyl amino acids and glycopeptides by 
an anomeric thiol group S-alkylation with β-iodo(or bromo)alanine has been described.30a Later, this 
methodology was modified to a “two-step one-pot” reaction, generating α-thio-linked glycosyl 
amino acids by condensation of a β-bromoalanine derivative with the corresponding thiolate salt.31 
We report herein new stereocontrolled entries to adequately protected S-glycosyl amino acids, 
mimics of the Tn antigen, as building blocks for solid phase peptide synthesis of S-linked 
glycopeptides, exploiting the reactivity of the sulfhydryl group of tri-O-acetyl-2-acetamido-2-
deoxy-1-thio-α-D-galactopyranose (1, abbreviated as GalNAc-α-SH) in two types of reactions. The 
first one comprises the hydrothiolation reaction of double bonds included in the side chains of 
amino acid derivatives. This reaction has been extensively used in glycochemistry.32 Moreover, the 
mild reaction conditions, atom economy, and regioselectivity of this process satisfy essential 
requirements of the click concept.33 The second type of reaction assayed involves the anomeric thiol 
group S-alkylation with bromo-amino acid derivatives. 
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To know the viability of this project, we started with the synthesis of the shortest glycopeptide (S-
glycosyl amino acid ended in amide groups) that includes the largest distance between carbohydrate 
and peptide backbone moieties. We selected GalNAc-α-SH (1) as a glycosyl donor, whose synthesis 
was made following the procedure described in the literature34a but properly modified to carry out in 
a gram scale (Supporting Information). GalNAc-α-SH (1) was subjected to an alkene 
hydrothiolation reaction with O-allyl serine derivative 2b-Ser, which was prepared according to the 
procedure described34b from commercially available N-Boc-serine derivative 2a-Ser. The 
hydrothiolation reaction was carried out using azobisisobutyronitrile (AIBN) as a radical initiator. 
The best conditions involved the use of 1.7 equivalents of thiol 1, 1.2 equivalents of AIBN and 1.0 
equivalent of alkene 2b-Ser to afford compound 3 in a 56% yield (Scheme 1). This derivative was 
transformed into the required diamide 6. Deprotection of Boc group, followed by acetylation of the 
amino group gave compound 4. This compound was subjected to hydrogenolysis of benzyl ester 
and the corresponding carboxylic acid was transformed into methyl amide. Diamide derivative 5 
was deacetylated to give target compound 6 (Scheme 1). 
 
 
 
 
 
 
 
Scheme 1. Synthesis of S-glycosyl amino acid 6 as a diamide. 
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Encouraged by this result, we synthesized the corresponding Fmoc-protected S-glycosyl amino 
acids 10-Ser/Cys/Thr, ready to use in SPPS and in a gram scale. To this aim, it was necessary to 
prepare the (O or S)-allyl N-Fmoc-serine/cysteine/threonine tert-butyl esters 9-Ser/Cys/Thr, which 
had not been described to date. Their synthesis started from commercially available N-Boc-amino 
acids 2a-Ser/Cys/Thr, whose Boc groups were removed, giving amino acids 7-Ser/Cys/Thr. The 
amino groups of these compounds were then protected as Fmoc carbamates, affording compounds 
8-Ser/Cys/Thr. Esterifications of acids 8-Ser/Cys/Thr with tert-butyl alcohol gave the required 
allylic derivatives 9-Ser/Cys/Thr (Scheme 2). 
 
 
 
 
Scheme 2. Synthesis of N-Fmoc-Ser/Cys/Thr(O- or S-allyl)-OtBu derivatives 9-Ser/Cys/Thr. 
As a next step, we assayed hydrothiolation reactions between glycosyl-thiol 1 and alkenes 9-
Ser/Cys/Thr, following the conditions above described for compound 2b-Ser, obtaining good 
yields of the required building blocks 10-Ser and 10-Thr (70% and 71%, respectively). However, 
compound 10-Cys was obtained only in a 20% yield (Scheme 3). To increase these yields, the 
photochemical version of the hydrothiolation reaction29a,b was tested because it is considered as a 
light-induced click reaction,35 with applications to diverse fields of study of biomolecular systems. 
We used a photochemical reactor equipped with 16 UVA (350 nm) lamps of 8 W. The reaction was 
initiated with 2,2-dimethoxy-2-phenylacetophenone (DPAP) and after testing several conditions, 
the best yields involved the use of 1.0 equiv. of alkene, 1.2 equiv. of compound 1 and 0.4 equiv. of 
DPAP in dichloromethane (1 mL). In this way, building blocks 10-Ser/Cys/Thr were obtained in a 
X
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53%, 30% and 62%, respectively (Scheme 3). It is well-known that this type of reactions involving 
O- or S-allyl derivatives works with moderate to low yields.36 We also tested a recent method with 
9-Ser/Cys/Thr, involving the use of BEt3 as an initiator and catechol as a co-reagent.
37 Although, 
only a slight improvement of the yield was achieved, this method provided an improved way to 
purify the desired compounds (Scheme 3). 
 
 
 
 
Scheme 3. Synthesis of S-glycosyl amino acid building blocks 10-Ser/Cys/Thr and 12 via 
hydrothiolation. TW, PW and RW stand for thermal way, photochemical way and repairing way, 
respectively. 
Compound 12, which contains a three-methylene bridge between S-α-GalNac and amino acid 
moieties, was synthesized following the same hydrothiolation protocol, tested again by both thermal 
and photochemical ways, starting from α-allylglycine 11. This protected compound was obtained 
according to the protocol previously published38 and it was reacted with glycosyl donor 1, giving a 
70% and 50% yield of desired building block 12 in thermal and phochemical ways, respectively 
(Scheme 3). We also tested the repairing way using catechol/BEt3 achieving compound 12 in a 
better yield than photochemical way (70%).   
To access to GalNAc-S-glycosylated building blocks 14 and 16, L-homocysteine (hCys) and L-
cysteine (Cys) derivatives, respectively, we used a different methodology based on the anomeric 
thiol group S-alkylation with bromo-amino acid derivatives (Scheme 4). This methodology has been 
above-commented30a,31 as well as their difficulties to carry out the nucleophilic substitution in a 
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basic medium in the presence of Fmoc protecting groups. We followed a recently published mild 
synthetic strategy39 that simply requires activated molecular sieves to selectively promote S-
alkylation. Therefore, activated molecular sieves (4Å) were employed as a base to promote S-
alkylation of GalNAc-α-SH 1 with appropriate protected γ-bromohomoalanine40 13 and β-
bromoalanine30,41 15 using dry DMF as a solvent (Scheme 4). 
 
 
 
 
Scheme 4. Synthesis of S-glycosyl amino acid building blocks 14 and 16 via nucleophilic 
substitution. 
Although the reactions proceeded with moderate yields, the procedure was easy to perform, fast, 
and provided similar overall yields when it was compared with other methods published recently.28 
These known bromo-derivatives 13 and 15 were obtained from L-homoserine and L-serine, 
respectively, following the procedure described in the literature, that involved N-Fmoc protection, 
tert-butyl ester formation and bromination under standard conditions.30 
These six mimics of the Tn antigen (10-Ser/Cys/Thr, 12, 14 and 16), all of S-glycosyl amino acids 
whose amino, carboxylic acid and hydroxyl groups are protected as N-Fmoc, tert-butyl esters and 
acetates, respectively, are adequate building blocks for SPPS of glycopeptides. Consequently, they 
were used to synthesize different α-S-neoglycopeptides shown in Scheme 5. The synthesis of these 
compounds was performed using the automated SPPS protocol with a Rink amide MBHA resin and 
Fmoc and side chain protected amino acids. α-S-Glycosylamino acid building blocks 10-
Ser/Cys/Thr, 12, 14 and 16 were manually coupled to the peptide sequence to improve the yield of 
O
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this step. After removal of the acetyl groups of the carbohydrate with a mixture of NH2NH2/MeOH, 
α-S-neoglycopeptides were released from the resin using trifluoroacetic acid (TFA). Under these 
conditions, all the acid-labile side-chain protecting groups were also removed. Purification by 
preparative HPLC and subsequent lyophilization gave the target α-S-neoglycopeptides 17-22 in 
good overall yields. 
 
Scheme 5. α-S-neoglycopeptides synthesized in this work. 
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The conformational behavior of the synthesized neoglycopeptides in solution was then deduced by 
using NMR. In particular, NOE data, supported by molecular dynamics (MD) simulations with 
time-averaged restraints (MD-tar), were employed.42,43 In a first step, full assignment of the protons 
in all derivatives was carried out using standard COSY and HSQC experiments. 2D-NOESY 
experiments in H2O/D2O (9/1) (25 °C, pH = 5.5) were then performed (Figure 2 and Supporting 
Information). Distances involving NH protons were semi-quantitatively deduced by integrating the 
volume of the corresponding cross-peaks. This experimental data was used as restraints in MD-tar 
simulations (Figure 2 and Supporting Information). 
 
 
 
 
 
 
 
 
 
Figure 2. Section of the 500 ms 2D NOESY spectrum (400 MHz) in H2O/D2O (9:1) at 25 °C of 
derivative 18, showing the amide region. Diagonal peaks and exchange cross-peaks connecting NH 
protons and water are negative (green color). The NOE contacts are represented as positive cross-
peaks (blue color). Comparison of the experimental and MD-tar derived distances for this 
glycopeptide is also shown. 
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The structure ensembles obtained through the MD-tar simulations indicate that the 
neoglycopeptides are rather flexible in solution (Figure 3 and Supporting Information). 
 
 
 
 
 
 
 
 
 
 
Figure 3. Ensembles obtained through 20 ns MD-tar simulations for neoglycopeptides 17-22. The 
backbone is shown in green and the GalNAc in purple.  
In general, the studied neoglycopeptides exhibit a random-coil conformation for the peptide 
backbone. This result was corroborated by circular dichroism (CD) spectroscopic studies 
(Supporting Information). The CD spectra of these derivatives differed from the one observed for 
the natural APDT(α-O-GalNAc)RP glycopeptide, which adopts mainly a PPII conformation for the 
peptide backbone in water44 (Supporting Information). As a point of interest, the contacts between 
the sugar and the peptide fragment are almost insignificant. As a consequence, the glycosylated 
residue exhibits a helix-like conformation in all studied compounds (Figure 4a for compound 22 
and Supporting Information for the other compounds). This feature is corroborated by the medium-
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size NOE intensities observed for the NHXaa4−HαXaa4, and NHArg5−HαXaa4 cross-peaks, where Xaa is 
the glycosylated residue.45 Conversely, it has been shown that GalNAc-glycosylation of the natural 
Ser or Thr residues forces these amino acids to display extended conformations46-52 due to the 
presence of stabilizing contacts between the sugar and the peptide moieties.46a,50 
 
Figure 4. (a) Definition of the glycosidic linkage in this work, together with φ/ψ distribution 
obtained through 20 ns MD-tar simulations for amino acid Thr4 in compound 22. (b) Type I β-turn 
conformer found in water for glycopeptides 19-22. (c) φ/ψ distribution obtained through 20 ns MD-
tar simulations for the glycosidic linkage in compound 22. The conformation found in the crystal 
structure for the glycosidic linkage of APDC(GalNAc)RP in complex to SM3 antibody (PDB id: 
5A2L, ref. 44) is represented as a red circle. 
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Of note, compounds 19-22, which are bearing a longer linker, adopt a low population (<25%) of a 
type I β-turn-like, stabilized by a hydrogen bond between Pro2 (CO) and Arg5 (NH), which has 
been reported for natural MUC1-like derivatives52 (Figure 4b). 
Concerning the S-glycosidic linkage, as stated by us for other derivatives,34 it is rather flexible in all 
compounds, with two main conformations, characterized by ψ ca. 180o or 60o, corresponding to the 
local minima calculated for methyl 4-thio-α-maltoside.53 The studied glycopeptides display a 
conformation centered at φ/ψ ≈ 60o/−60o degrees, also close to that observed in the crystal structure 
of a mucin-like glycopeptide incorporating GalNAc-Cys44 (Figure 4c and Supporting Information).  
Regarding the lateral chain, derivatives carrying a serine, homoserine or homohomoserine 
(compounds 18, 19 and 20, respectively) present a flexible dihedral angle χ1, with two main values 
(Supporting Information). This result is similar to that found for other glycopeptides bearing a 
serine residue.49 For the other derivatives, χ1 is fixed around 60 degrees. Glycopeptides 20, 21 and 
22 present a similar behavior for the side chain, being derivative 22, with a threonine amino acid, 
the one with the more rigid linker in solution (Supporting Information). The result is in agreement 
with our previous studies on Thr-derived glycopeptides.50 In general, and according to our 
simulations, the linker of all glycopeptides is located almost perpendicularly to the peptide 
backbone (Figure 3 and Supporting Information).  
The viability of these novel compounds as mimics of MUC1 antigen was validated by the analysis 
of the crystal structure of one of these unnatural glycopeptides, compound 22, complexed to the 
anti-MUC1 monoclonal antibody SM3 produced in our lab.44 The analysis of the X-ray structure 
(PDB id: 5fxc, Figure 5a and Supporting Information) revealed that the hydrogen bonds, as well as 
the hydrophobic contacts present in the natural glycopeptide APDT(GalNAc)RP bound to SM3,44 
are also conserved in the scFv-SM3:22 complex. In detail, Pro2 stacks with Trp91L, Trp96L and 
Tyr32L. The side-chains of Asp3 and Arg5 are engaged in hydrophobic contacts with Trp33H and 
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Tyr32H, respectively. NH group of Ala1 and carbonyl group of Thr4 are involved in hydrogen 
bonds with Tyr32L and Gln97H, respectively. A hydrogen bond between side chain of Arg5 and 
carbonyl group of Asn31H was also observed. 
 
 
 
 
 
Figure 5. (a) Crystal structure of glycopeptide 22 in complex with scFv-SM3, showing the 
stabilizing interactions antigen-antibody. Carbon atoms of glycopeptide 22 are in green. Carbon 
atoms of key residues of SM3 are coloured in yellow. Interactions between the peptidic fragment 
and SM3 surface are in pink. (b) Superposition of the peptide backbone of glycopeptide 
APDT(GalNAc)RP and glycopeptide 22 in complex with scFv-SM3, showing the root-mean-square 
deviation (rmsd) value for the peptide backbone. (c) Ensembles obtained from the unrestrained 100 
ns MD simulations performed on complex scFv-SM3:22. The antibody is shown as a grey surface 
and the peptide backbone of glycopeptide 22 is shown in green. The carbon atoms of GalNAc unit 
are in pink. The conformation of glycopeptide APDT(GalNAc)RP found in the X-ray structure is 
also shown in purple-blue (PDB id: 5A2K, ref. 44).  
 
The conformation of the peptide fragment of 22 bound to the mAb is almost identical to those 
observed for natural glycopeptides in complex with this antibody, indicating the minor impact that 
the linker has on the peptide conformation in the bound state (Figure 5b). Unfortunately, the 
structure of the linker and the GalNAc, could not be solved due to the lack of electron density. This 
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is presumably due to the high degree of flexibility of the linker. Therefore, molecular dynamics 
(MD) simulations (100 ns) were performed. All interactions between glycopeptide 22 and the mAb 
observed in the X-ray structure are also observed though MD simulations. As deduced from these 
calculations, the linker is rather flexible and the GalNAc residue is exposed to the solvent (Figure 
5c).  
Conclusions 
Several sulfa-Tn antigen derivatives with variable lengths between the glycan and the peptide 
backbone have been synthesized using two types of reactions with GalNAc(OAc)3-α-SH. The first 
one comprised a thiol-ene coupling of alkenyl-α-amino acids and the second one involved an 
anomeric thiol group S-alkylation of bromo-α-amino acids. The presence of a linker between the 
peptide backbone and the sugar precludes the intramolecular interactions between these two 
moieties, favoring the presentation of the sugar for molecular recognition events. This property, 
together with the potential lack of immunosuppression suffered by the natural derivatives, makes 
the studied compounds promising candidates for the design of novel therapeutic vaccines to treat 
tumors. 
Experimental Section 
Reagents and general procedures. Commercial reagents were used without further purification. Analytical thin layer 
chromatography (TLC) was performed on Macherey-Nagel precoated aluminium sheets with a 0.20 mm thickness of 
silica gel 60 with fluorescent indicator UV254. TLC plates were visualized with UV light and by staining with 
phosphomolybdic acid (PMA) solution (5 g of PMA in 100 mL of absolute ethanol) or sulfuric acid-ethanol solution. 
Column chromatography was performed on silicagel (230−400 mesh). 1H and 13C NMR spectra were measured with a 
400 MHz spectrometer with TMS as the internal standard. Multiplicities are quoted as singlet (s), broad singlet (br s), 
doublet (d), doublet of doublets (dd), triplet (t), or multiplet (m). Spectra were assigned using COSY and HSQC 
experiments. All NMR chemical shifts (δ) were recorded in ppm and coupling constants (J) were reported in Hz. The 
results of these experiments were processed with MestreNova software. High resolution electrospray mass (ESI) spectra 
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were recorded on a microTOF spectrometer; accurate mass measurements were achieved by using sodium formate as an 
external reference.   
General procedure for the thiol-ene coupling by thermal way. To a solution of alkene-amino acid derivative (1.0 
equiv) and tri-O-acetyl-2-acetamido-2-deoxy-1-thio-α-D-galactopyranose 1 (1.7 equiv) in CHCl3 (5 mL), α,α′-
azoisobutyronitrile (AIBN or VAZO 64, Molekula 78-67-1) (0.6 equiv) was added and reaction mixture was then heated 
at reflux. After stirring for 3 h, another portion of AIBN (0.6 equiv) was added and the mixture was stirred for 4 h more. 
The reaction was concentrated and the residue was purified by a silica gel column chromatography to give the 
corresponding S-galactosaminyl amino acid derivative. 
General procedure for the thiol-ene coupling by photochemical way. The reaction was carried out in a glass vial 
(diameter: 2 cm), sealed with a natural rubber septum, located 2.5 cm away from the UVA lamp apparatus (LUZCHEM -
LZC-4V-, 16 UVA-lamps of 350 nm and 8 W). To a solution of alkene-amino acid derivative (1.0 equiv) and tri-O-acetyl-
2-acetamido-2-deoxy-1-thio-α-D-galactopyranose 1 (1.2 equiv) in CH2Cl2 (2.5 mL), 2,2-dimethoxy-2-
phenylacetophenone (DPAP) (0.2 equiv) was added. After stirring for 3 h, another portion of DPAP (0.2 equiv) was added 
and the mixture was stirred for 4 h more. The reaction was concentrated and the residue was purified by a silica gel 
column chromatography to give the corresponding S-galactosaminyl amino acid derivative.  
General procedure for the thiol-ene coupling by repairing way. To a solution of tri-O-acetyl-2-acetamido-2-deoxy-1-
thio-α-D-galactopyranose 1 (2.0 equiv), catechol (1.2 equiv) and alkene-amino acid derivative (0.75 M in CH2Cl2, 1.0 
equiv), BEt3 (1.0 M in hexane, 1.2 equiv) was added. The reaction was stirred at room temperature and BEt3 was regularly 
added until complete consumption of the alkenyl-amino acid derivative (0.1 equiv every 45 min). The reaction was then 
concentrated and the residue was purified by a silica gel column chromatography to give the corresponding S-
galactosaminyl amino acid derivative. 
Solid-phase (glyco)peptide synthesis (SPPS). All glycopeptides were synthesized by a stepwise solid-phase peptide 
synthesis using the Fmoc strategy on Rink Amide MBHA resin (128 mg, 0.1 mmol, loading of the resin: 0.78 mmol/g). 
The glycosylated amino acid building block (2.0 equiv) was manually coupled using HBTU, while the other Fmoc amino 
acids (10.0 equiv) were automatically coupled on an Applied Biosystems 433A peptide synthesizer using HBTU. The O-
acetyl groups of (AcO)3GalNAc moiety were removed in a mixture of NH2NH2/MeOH (7:3). The glycopeptides were 
then released from the resin and all acid sensitive side-chain protecting groups were simultaneously removed using TFA 
95%, TIS 2.5%, H2O 2.5%, followed by precipitation with diethyl ether. Finally, all glycopeptides were purified by HPLC 
on a Waters Delta Prep 4000 reverse phase HPLC and Waters 2987 Dual Absorbance Detector, using a Phenomenex Luna 
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C18(2) column (10 µ, 250 mm × 21.2 mm), 2% (v/v) CH3CN in H2O (containing 0.1% v/v TFA) gradient to 13% CH3CN 
(t = 27 min) and then to 60% CH3CN (t = 33 min), 10 mL/min and registered at λ = 212 nm. 
3,4,6-Tri-O-acetyl-2-acetamido-2-deoxy-1-thio-α-D-galactopyranose (1)  
A stirred suspension of a mixture of α,β-anomers of 1,3,4,6-tetra-O-acetyl-2-acetamido-2-deoxy-D-galactopyranose (20.5 
g, 52.65 mmol) and Lawesson’s reagent (18.1 g, 44.7 mmol) in (1:1) toluene/1,2-dichloroethane solution (200 mL) was 
heated at 80 °C for 12 h. The reaction was then evaporated and the crude used directly in the next reaction. This crude was 
dissolved in 200 mL of methanol and stirred at 0 °C. TFA (10 mL) and water (10 mL) were then added, and the reaction 
was allowed to warm to room temperature and stirred for 4 h. The reaction was concentrated and the residue was purified 
by column chromatography using EtOAc/CH2Cl2 (8:2) as eluent, to give compound 1 (9.55 g, 50%) as a white foam. 
Spectroscopic data are consistent with the literature (ref. 26b and 34a). 
 
N-Boc-O-(S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)mercaptopropyl)-L-serine benzyl 
ester (3) 
A solution of N-Boc-L-Ser(O-allyl)-OBn (2b-Ser) (90 mg, 0.27 mmol), 3,4,6-tri-O-acetyl-2-acetamido-2-deoxy-1-thio-α-
D-galactopyranose (1) (166 mg, 0.46 mmol) and AIBN (27 mg, 0.16 mmol) in CHCl3 (3 mL) was heated at reflux. After 
stirring for 3 h, another portion of AIBN (27 mg, 0.16 mmol) was added and the reaction was stirred for 4 h more. The 
reaction mixture was cooled, concentrated, and then chromatographed on silica gel using EtOAc/CH2Cl2 (8:2) as eluent to 
give compound 3 (104 mg, 56%) as a white foam. [α]D
20 (c=1.00, CHCl3): +71.4. HRMS (ESI+) (m/z) 699.2791 
[M+H]+; calculated C32H47N2O13S
+: 699.2793. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.39–7.29 (m, 5H, arom), 5.58 (d, J 
= 8.6 Hz, 1H, NH sugar), 5.45 (d, J = 5.1 Hz, 1H, H1), 5.41–5.34 (m, 2H, NH, H4), 5.25 (d, J = 12.4 Hz, 1H, CH2Bn), 5.13 
(d, J = 12.4 Hz, 1H, CH2Bn), 5.03 (dd, J = 11.6, 2.7 Hz, 1H, H3), 4.81–4.71 (m, 1H, H2), 4.51 (t, J = 6.4 Hz, 1H, H5), 
4.49–4.43 (m, 1H, Hα), 4.16–4.03 (m, 2H, 2H6), 3.84 (dd, J = 9.4, 2.6 Hz, 1H, Hβ), 3.64 (dd, J = 9.4, 3.2 Hz, 1H, Hβ), 
3.51–3.35 (m, 2H, 2Hδ), 2.67–2.47 (m, 2H, 2Hζ), 2.15 (s, 3H, COCH3), 2.03–1.95 (m, 9H, COCH3, COCH3, NHCOCH3), 
1.87–1.71 (m, 2H, 2Hε), 1.44 (s, 9H, C(CH3)3).
 13C NMR (100 MHz, CDCl3) δ (ppm): 171.1, 170.7, 170.5, 170.4, 170.2, 
155.6 (CO), 135.6, 128.7, 128.5, 128.3 (arom), 85.3 (C1), 80.2 (C(CH3)3), 71.0 (Cβ), 69.7 (Cδ), 68.6 (C3), 67.5 (C4, C5), 
67.2 (CH2Bn), 62.0 (C6), 54.3 (Cα), 48.5 (C2), 29.8 (Cε), 28.5 (C(CH3)3), 28.0 (Cζ), 23.5 (NHCOCH3), 20.8 (3 COCH3). 
 
N-Acetyl-O-(S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)mercaptopropyl)-L-serine benzyl 
ester (4) 
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Trifluoroacetic acid (378 µL, 4.91 mmol) was added over a solution of compound 3 (104 mg, 0.15 mmol)  in CH2Cl2 (8 
mL) and the resulting solution was stirred for 2 h at room temperature and the solvent was removed under reduced 
pressure. The residue was dissolved in Et2O (20 mL) and then evaporated. This operation was repeated several times to 
obtain the corresponding compound, which was used directly in the next reaction. Acetic anhydride (2.0 mL) and pyridine 
(4 mL) were added to previous compound, and the solution was stirred for 12 h at room temperature. The solvent was 
removed under reduced pressure and the residue was chromatographed on silica gel using CH2Cl2/MeOH (9:1) as eluent 
to give compound 4 (67 mg, 70%) as a white foam. [α]D
20 (c=1.01, CHCl3): +81.9. HRMS (ESI+) (m/z) 641.2382 
[M+H]+; calculated C29H41N2O12S
+: 641.2375. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.43–7.22 (m, 5H, arom), 6.42 (d, J 
= 8.0 Hz, 1H, NH), 5.57 (d, J = 8.7 Hz, 1H, NH sugar), 5.48 (d, J = 5.2 Hz, 1H, H1), 5.38 (s, 1H, H4), 5.25 (d, J = 12.3 
Hz, 1H, CH2Bn), 5.16 (d, J = 12.3 Hz, 1H, CH2Bn), 5.04 (dd, J = 11.7, 2.5 Hz, 1H, H3), 4.83–4.71 (m, 2H, Hα, H2), 4.51 
(t, J = 6.4 Hz, 1H, H5), 4.17–4.05 (m, 2H, 2H6), 3.86 (dd, J = 9.3, 1.5 Hz, 1H, Hβ), 3.69–3.63 (m, 1H, Hβ), 3.52–3.46 (m, 
1H, Hδ), 3.43–3.35 (m, 1H, Hδ), 2.66–2.58 (m, 1H, Hζ), 2.55–2.48 (m, 1H, Hζ), 2.15 (s, 3H, COCH3), 2.08–1.95 (m, 
12H, COCH3, COCH3, NHCOCH3, NHCOCH3), 1.86–1.72 (m, 2H, 2Hε). 
13C NMR (100 MHz, CDCl3) δ (ppm): 171.1, 
170.5, 170.1, 170.2, 170.3 (6 CO), 135.5, 128.7, 128.5, 128.2 (arom), 85.1 (C1), 70.7 (Cβ), 69.4 (Cδ), 68.5 (C3), 67.4 
(C4, C5), 67.3 (CH2Bn), 61.8 (C6), 52.8 (Cα), 48.5 (C2), 29.7 (Cε), 27.6 (Cζ), 23.3 (NHCOCH3), 23.2 (NHCOCH3), 20.8, 
20.8 (3 COCH3).  
N-Acetyl-O-(S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)mercaptopropyl)-L-serine methyl 
amide (5) 
A solution of compound 4 (67 mg, 0.10 mmol) in MeOH (10 mL) was treated with hydrogen under atmospheric pressure 
at room temperature, using Pd/C 10% as a catalyst (67 mg). This reaction mixture was stirred for 24 h. The solution was 
then filtered over celite, evaporated and this crude was used directly in the next reaction. It was dissolved in dry CH3CN 
(20 mL) under an inert atmosphere. Methylamine hydrochloride (21 mg, 0.31 mmol), TBTU (44 mg, 0.14 mmol) and 
DIEA (91 µL, 0.52 mmol) were then added and the reaction was stirred at room temperature for 24 h. After evaporation, 
the residue was purified by a silica gel column chromatography, eluting with CH2Cl2/MeOH (9:1), to give compound 5 
(27 mg, 46%) as a yellow oil. [α]D
20 (c=1.00, CHCl3): +101.4. HRMS (ESI+) (m/z) 564.2234 [M+H]
+; calculated 
C23H38N3O11S
+: 564.2222. 1H NMR (400 MHz, CDCl3) δ (ppm): 6.71–6.60 (m, 2H, NHCOCH3, NHCH3), 6.00 (t, J = 
8.4 Hz, 1H, NH sugar), 5.53 (dd, J = 8.0, 5.4 Hz, 1H, H1), 5.38–5.36 (m, 1H, H4), 5.04 (dt, J = 11.8, 3.1 Hz, 1H, H3), 
4.75–4.66 (m, 1H, H2), 4.55–4.47 (m, 2H, H5, Hα), 4.14–4.07 (m, 2H, 2H6), 3.77 (ddd, J = 14.4, 9.4, 4.6 Hz, 1H, Hβ), 
3.61–3.43 (m, 3H, Hβ, 2Hδ), 2.81 (d, J = 4.8 Hz, 3H, NHCH3), 2.73–2.58 (m, 2H, 2Hζ), 2.14 (s, 3H, COCH3), 2.06–1.95 
(m, 12H, COCH3, COCH3, NHCOCH3, NHCOCH3), 1.92–1.77 (m, 2H, 2Hε). 
13C NMR (100 MHz, CDCl3) δ (ppm) 
(Duplication of signals are observed, probably due to the coexistence of various conformers, since when the spectra were 
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registered at higher temperature some of them collapse in one signal): 171.2, 170.6, 170.6, 170.5, 170.3, 170.3 (CO), 
85.4, 85.4 (C1), 70.1, 70.1 (Cβ), 69.3, 69.2 (Cδ), 68.5 (C3), 67.6, 67.5, 67.4, 67.4 (C4, C5), 61.9, 61.9 (C6), 52.8, 52.8 
(Cα), 48.8, 48.7 (C2), 29.7, 29.6 (Cε), 28.0, 27.9 (Cζ), 26.5 (NHCH3), 23.4, 23.4 (NHCOCH3), 23.3, 23.3 (NHCOCH3), 
20.9, 20.8, 20.8 (3 COCH3).  
 
N-Acetyl-O-(S-((2-acetamido-2-deoxy)-α-D-galactopyranosyl)mercaptopropyl)-L-serine methyl amide (6) 
To a solution of compound 5 (27 mg, 0.05 mmol) in MeOH (2 mL), MeONa (0.5 M, 150 µL) was added and the reaction 
was stirred at room temperature for 2 h. Then, Dowex 50W-X8 (40 mg) was added to the reaction and it was stirred for 10 
min. After that, the mixture was filtered and evaporated obtaining compound 6 in a 90% yield. In order to perform ELLA 
test, the residue was dissolved in H2O (0.5 mL) and compound 6 was purified by semipreparative HPLC analysis using 
the following procedure: 0.5 mL injection loop was conducted on a Waters Delta Prep 4000 reverse phase HPLC and 
Waters 2987 Dual Absorbance Detector, using a Phenomenex Luna C18(2) column (10 µ, 250 mm × 21.2 mm), 5% (v/v) 
CH3CN in H2O (containing 0.1% v/v TFA) gradient to 30% CH3CN (t = 30 min), 10 mL/min, λ = 212 nm to furnish 6 (10 
mg, 50%, tR 25.3 min) as a white foam after lyophilization. [α]D
20 (c=1.00, CHCl3): +85.0. HRMS (ESI+) (m/z) 438.1911 
[M+H]+; calculated C17H32N3O8S
+: 438.1905. 1H NMR (400 MHz, H2O/D2O 9:1) δ (ppm) amide protons: 8.20 (d, J = 
5.5 Hz, 1H, NHCOCH3), 8.13 (d, J = 7.6 Hz, 1H, NH sugar), 7.91 (s, 1H, NHCH3). 
1H NMR (400 MHz, D2O) δ (ppm): 
5.50 (d, J = 5.5 Hz, 1H, H1), 4.46 (t, J = 4.9 Hz, 1H, Hα), 4.35 (dd, J = 11.4, 5.5 Hz, 1H, H2), 4.28 (t, J = 6.1 Hz, 1H, 
H5), 4.00 (d, J = 2.4 Hz, 1H, H4), 3.84 (dd, J = 11.4, 3.1 Hz, 1H, H3), 3.80–3.71 (m, 4H, 2H6, 2Hβ), 3.69–3.55 (m, 2H, 
2Hδ), 2.75 (s, 3H, NHCH3), 2.72–2.61 (m, 2H, 2Hζ), 2.07 (s, 3H, NHCOCH3), 2.05 (s, 3H, COCH3), 1.94–1.81 (m, 2H, 
2Hε). 13C NMR (100 MHz, D2O) δ (ppm): 174.6, 174.6, 172.2 (CO), 83.9 (C1), 71.7 (C5), 69.2 (Cβ, Cδ), 68.6 (C4), 67.8 
(C3), 61.3 (C6), 54.0 (Cα), 50.3 (C2), 28.5 (Cε), 26.8 (Cζ), 26.1 (NHCH3), 22.0 (NHCOCH3), 21.9 (NHCOCH3). 
 
N-Fmoc-O-(allyl)-L-serine tert-butyl ester (9-Ser) 
To a solution of compound 2a-Ser (1.02 g, 4.16 mmol) in CH2Cl2 (5 mL), trifluoroacetic acid (5 mL) was added. The 
resulting solution was stirred for 2 h at room temperature and the solvent was removed under reduced pressure. The 
residue was dissolved in Et2O (10 mL) and then evaporated. This operation was repeated several times to obtain 
compound 7-Ser, which was used directly in the next reaction. A solution of acetone/H2O (1:1) (30 mL) was added to the 
previous compound and it was then treated with Na2CO3 (882 mg, 8.32 mmol) and FmocOSu (1.4 g, 4.16 mmol). The 
mixture was stirred for 18 h at room temperature and concentrated. The crude mixture was diluted with H2O and extracted 
with Et2O. The aqueous layer was then acidified to pH 3-4 with a 10% KHSO4 solution. This aqueous solution was 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, 
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and concentrated to give compound 8-Ser (1.50 g, 98%) as a white solid, which was used directly in the next reaction. 
tButyl alcohol (1.6 mL, 16.73 mmol) was added over DCC (2.72 g, 13.07 mmol) and CuCl (40 mg, 0.41 mmol) under 
inert atmosphere, light protected, and the resulting mixture was stirred for 5 days and dry CH2Cl2 (6 mL) was then added. 
After that, compound 8-Ser (1.50 g, 4.08 mmol) dissolved in dry CH2Cl2 (6 mL) was added over the previous solution 
and the mixture was stirred for 4 h. The dicyclohexylurea byproduct was removed by filtration over celite, and the 
solution was washed with saturated NaHCO3 (2 x 50 mL). The organic layer was dried, filtered and concentrated, and the 
residue was purified by silica gel column chromatography using hexane/EtOAc (8:2) as eluent, to give compound 9-Ser 
(1.0 g, 58%) as a colorless oil. [α]D
20 (c=1.00, CHCl3): +16.5. HRMS (ESI+) (m/z) 446.1943 [M+Na]
+; calculated 
C25H29NNaO5
+: 446.1938. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.80–7.73 (m, 2H, arom), 7.65–7.59 (m, 2H, arom), 
7.44–7.36 (m, 2H, arom), 7.34–7.28 (m, 2H, arom), 5.86 (m, 1H, Hε), 5.67 (d, J = 8.3 Hz, 1H, NH), 5.27 (d, J = 17.3 Hz, 
1H, Hζtrans), 5.20 (d, J = 10.4 Hz, 1H, Hζcis), 4.47–4.33 (m, 3H, Hα, CH2Fmoc), 4.24 (t, J = 7.2 Hz, 1H, CHFmoc), 4.04 
(dd, J = 12.8, 5.3 Hz, 1H, Hδ), 3.96 (dd, J = 12.8, 5.4 Hz, 1H, Hδ), 3.86 (dd, J = 9.4, 2.5 Hz, 1H, Hβ), 3.69 (dd, J = 9.3, 
2.2 Hz, 1H, Hβ), 1.49 (s, 9H, C(CH3)3). 
13C NMR (100 MHz, CDCl3) δ (ppm): 169.5 (CO), 156.2 (CO), 144.1, 144.0, 
141.4 (arom), 134.2 (Cε), 127.8, 127.2, 125.3, 120.1 (arom), 117.5 (Cζ), 82.4 (C(CH3)3), 72.4 (Cδ), 70.4 (Cβ), 67.3 
(CH2Fmoc), 55.1 (Cα), 47.3 (CHFmoc), 28.2 (C(CH3)3).  
 
N-Fmoc-S-(allyl)-L-cysteine tert-butyl ester (9-Cys) 
Following the same procedure above described for compound 9-Ser and starting from 2a-Cys (0.76 g, 2.91 mmol), 
compound 9-Cys (679 mg) was obtained as a white solid with a 54% overall yield.  
Mp: 61–63 ºC. [α]D
20 (c=1.00, CHCl3): -6.0. HRMS (ESI+) (m/z) 440.1896 [M+H]
+; calculated C25H30NO4S
+: 440.1890. 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.78–7.76 (m, 2H, arom), 7.64–7.60 (m, 2H, arom), 7.43–7.38 (m, 2H, arom), 
7.35–7.29 (m, 2H, arom), 5.82–5.71 (m, 1H, Hε), 5.62 (d, J = 7.7 Hz, 1H, NH), 5.16–5.08 (m, 2H, 2Hζ), 4.50 (m, 1H, 
Hα), 4.40 (d, J = 7.1 Hz, 1H, CH2Fmoc), 4.25 (t, J = 7.1 Hz, 1H, CHFmoc), 3.18–3.15 (m, 2H, 2Hδ), 2.97 (dd, J = 13.8, 4.5 
Hz, 1H, Hβ), 2.87 (dd, J = 13.8, 5.6 Hz, 1H, Hβ), 1.50 (s, 9H, C(CH3)3). 
13C NMR (100 MHz, CDCl3) δ (ppm): 169.9 
(CO), 155.8 (CO), 144.0, 143.9, 141.4 (arom), 133.9 (Cε), 127.8, 127.2, 125.2, 120.1 (arom), 117.9 (Cζ), 82.9 (C(CH3)3), 
67.2 (CH2Fmoc), 54.2 (Cα), 47.2 (CHFmoc), 35.5 (Cδ), 33.3 (Cβ), 28.1 (C(CH3)3).  
 
N-Fmoc-O-(allyl)-L-threonine tert-butyl ester (9-Thr) 
Following the same procedure above described for compound 9-Ser and starting from 2a-Thr (2.24 g, 8.64 mmol), 
compound 9-Thr (2.03 g) was obtained as a white solid with a 59% overall yield.  
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Mp: 58–60 ºC. [α]D
20 (c=1.00, CHCl3): -0.3. HRMS (ESI+) (m/z) 438.2292 [M+H]
+; calculated C26H32NO5
+: 438.2275. 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.78–7.74 (m, 2H, arom), 7.68–7.63 (m, 2H, arom), 7.43–7.38 (m, 2H, arom), 
7.35–7.30 (m, 2H, arom), 5.94–5.82 (m, 1H, Hε), 5.60 (d, J = 9.6 Hz, 1H, NH), 5.29 (d, J = 17.0 Hz, 1H, Hζtrans), 5.19 
(d, J = 10.4 Hz, 1H, Hζcis), 4.48–4.38 (m, 2H, CH2Fmoc), 4.34 (dd, J = 9.6, 1.3 Hz, 1H, Hα), 4.26 (t, J = 7.2 Hz, 1H, 
CHFmoc), 4.14–4.06 (m, 2H, Hβ, Hδ), 3.91 (dd, J = 12.6, 5.5 Hz, 1H, Hδ), 1.51 (s, 9H, C(CH3)3), 1.25 (d, J = 6.2 Hz, 3H, 
CH3β). 
13C NMR (100 MHz, CDCl3) δ (ppm): 169.6 (CO), 156.7 (CO), 144.0, 143.8, 141.2 (arom), 134.5 (Cε), 127.6, 
127.0, 127.0, 125.1, 125.1, 119.9 (arom), 116.9 (Cζ), 81.8 (C(CH3)3), 74.7 (Cβ), 70.0 (Cδ), 67.1 (CH2Fmoc), 59.1 (Cα), 
47.1 (CHFmoc), 28.0 (C(CH3)3), 16.2 (CH3β). 
 
N-Fmoc-O-(S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)mercaptopropyl)-L-serine tert-
butyl ester (10-Ser) 
THERMAL WAY: A solution of 9-Ser (195 mg, 0.46 mmol), compound 1 (284 mg, 0.78 mmol) and AIBN (46 mg, 0.28 
mmol) in CHCl3 (5 mL) was heated at reflux. After stirring for 3 h, another portion of AIBN (46 mg, 0.28 mmol) was 
added and the reaction was stirred for 4 h more. The reaction mixture was cooled, concentrated and then chromatographed 
on silica gel using EtOAc/CH2Cl2 (8:2) as eluent to give protected glycosyl amino acid 10-Ser (253 mg, 70%) as a white 
solid.  
PHOTOCHEMICAL WAY: A solution of compound 9-Ser (232 m, 0.55 mmol), compound 1 (240 mg, 0.66 mmol) and 
DPAP (30 mg, 0.11 mmol) in CH2Cl2 (2.5 mL) was irradiated at λmax 365 nm. After stirring for 3 h, another portion of 
DPAP (30 mg, 0.11 mmol) was added and the reaction was stirred for 4 h more. The reaction mixture was then 
concentrated and the residue was chromatographed on silica gel using  EtOAc/CH2Cl2 (8:2) as eluent to give protected 
glycosyl amino acid 10-Ser (227 mg, 53%) as a white solid.  
REPAIRING WAY: A solution of compound 9-Ser (205 mg, 0.48 mmol), compound 1 (352 mg, 0.97 mmol), catechol 
(64 mg, 0.58 mmol) and BEt3 (84 µL, 0.58 mmol) in CH2Cl2 (0.65 mL) was stirred at room temperature. After stirring for 
1 h, another portion of BEt3 (7 µL) was added (until complete consumption of compound 9-Ser). The reaction mixture 
was then concentrated and the residue chromatographed on silica gel using EtOAc/CH2Cl2 (8:2) as eluent, to give 
protected glycosyl amino acid 10-Ser (265 mg, 70%) as a white solid. 
Physical data: mp: 63–65 ºC, [α]D
20 (c=1.00, CHCl3): +95.5. HRMS (ESI+) (m/z) 787.3119 [M+H]
+; calculated 
C39H51N2O13S
+: 787.3106. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.78–7.74 (m, 2H, arom), 7.65–7.59 (m, 2H, arom), 
7.42–7.37 (m, 2H, arom), 7.34–7.29 (m, 2H, arom), 5.70–5.60 (m, 2H, NHAc, NHFmoc), 5.49 (d, J = 5.2 Hz, 1H, H1), 
5.38 (s, 1H, H4), 5.04 (dd, J = 11.6, 2.6 Hz, 1H, H3), 4.82–4.72 (m, 1H, H2), 4.53 (t, J = 6.3 Hz, 1H, H5), 4.46–4.33 (m, 
3H, CH2Fmoc, Hα), 4.25 (t, J = 7.1 Hz, 1H, CHFmoc), 4.17–4.03 (m, 2H, 2H6), 3.82 (dd, J = 9.4, 2.8 Hz, 1H, Hβ), 3.67 (dd, 
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J = 9.3, 2.3 Hz, 1H, Hβ), 3.60–3.43 (m, 2H, 2Hδ), 2.75–2.57 (m, 2H, 2Hζ), 2.14 (s, 3H, COCH3), 2.06–1.95 (m, 9H, 2 
COCH3, NHCOCH3), 1.91–1.83 (m, 2H, 2Hε), 1.48 (s, 9H, C(CH3)3).
 13C NMR (100 MHz, CDCl3) δ (ppm): 171.1, 
170.4, 170.4, 170.2, 169.4, 156.1 (6 CO), 144.0, 144.0, 141.4, 127.8, 127.2, 125.3, 120.0 (arom), 85.2 (C1), 82.4 
(C(CH3)3), 71.2 (Cβ), 69.7 (Cδ), 68.6 (C3), 67.5, 67.4 (C4, C5), 67.2 (CH2Fmoc), 61.9 (C6), 55.0 (Cα), 48.5 (C2), 47.3 
(CHFmoc), 29.8 (Cε), 28.1 (C(CH3)3), 28.0 (Cζ), 23.4 (NHCOCH3), 20.8, 20.8 (3 COCH3). 
 
N-Fmoc-S-(S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)mercaptopropyl)-L-cysteine tert-
butyl ester (10-Cys) 
THERMAL WAY: Following the same procedure above described for compound 10-Ser and starting from 9-Cys (191 
mg, 0.43 mmol), compound 10-Cys (70 mg, 20%) was obtained as a white solid.  
PHOTOCHEMICAL WAY: Following the same procedure above described for compound 10-Ser and starting from 9-
Cys (203 mg, 0.46 mmol), compound 10-Cys (111 mg, 30%) was obtained as a white solid. 
REPAIRING WAY: Following the same procedure above described for compound 10-Ser and starting from 9-Cys (310 
mg, 0.71 mmol), compound 10-Cys (201 mg, 36%) was obtained as a white solid. 
Physical data: mp: 69–71 ºC, [α]D
20 (c=1.00, CHCl3): +82.9. HRMS (ESI+) (m/z) 803.2878 [M+H]
+; calculated 
C39H51N2O12S2
+: 803.2878. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.77–7.74 (m, 2H, arom), 7.62–7.58 (m, 2H, arom), 
7.41–7.36 (m, 2H, arom), 7.33–7.28 (m, 2H, arom), 5.69 (d, J = 8.0 Hz, 2H, NHAc, NHFmoc), 5.49 (d, J = 5.3 Hz, 1H, 
H1), 5.36 (d, J = 2.4 Hz, 1H, H4), 5.02 (dd, J = 11.7, 3.1 Hz, 1H, H3), 4.79–4.71 (m, 1H, H2), 4.54–4.44 (m, 2H, H5, 
Hα), 4.43–4.34 (m, 2H, CH2Fmoc), 4.22 (t, J = 7.0 Hz, 1H, CHFmoc), 4.15–4.03 (m, 2H, 2H6), 2.99 (dd, J = 13.7, 4.8 Hz, 
1H, Hβ), 2.92 (dd, J = 13.7, 5.1 Hz, 1H, Hβ), 2.75–2.13 (m, 4H, 2Hζ, 2Hδ), 2.13 (s, 3H, COCH3), 2.02–1.93 (m, 9H, 2 
COCH3, NHCOCH3), 1.91–1.82 (m, 2H, 2Hε), 1.48 (s, 9H, C(CH3)3). 
13C NMR (100 MHz, CDCl3) δ (ppm): 171.0, 
170.4, 170.3, 170.2, 169.8, 155.8 (6 CO), 143.9, 143.9, 141.4, 127.8, 127.2, 125.2, 120.1 (arom), 85.2 (C1), 83.0 
(C(CH3)3), 68.6 (C3), 67.5 (C5), 67.4 (C4), 67.2 (CH2Fmoc ), 61.9 (C6), 54.4 (Cα), 48.4 (C2), 47.2 (CHFmoc), 34.8 (Cβ), 
31.7 (Cδ), 29.9 (Cζ), 29.3 (Cε), 28.1 (C(CH3)3), 23.4 (NHCOCH3), 20.8, 20.8 (3 COCH3).  
The MS spectrum of the crude reaction mixture, before to be purified by column chromatography, showed signals 
corresponding to the expected product 10-Cys and side-products named 24, 26, 27, 28 and 29 that probably are formed by 
radical couplings as shown in the scheme shown in the Supporting Information. This feature may explain the low yield 
obtained in this reaction, following the tree methodologies, when it is compared with the formation of 10-Ser, 10-Thr or 
12.   
N-Fmoc-O-(S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)mercaptopropyl)-L-threonine tert-
butyl ester (10-Thr) 
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THERMAL WAY: Following the same procedure above described for compound 10-Ser and starting from 9-Thr (206 
mg, 0.47 mmol), compound 10-Thr (268 mg, 71%) was obtained as a white solid. 
PHOTOCHEMICAL WAY: Following the same procedure above described for compound 10-Ser and starting from 9-
Thr (160 mg, 0.37 mmol), compound 10-Thr (181 mg, 62%) was obtained as a white solid. 
REPAIRING WAY: Following the same procedure above described for compound 10-Ser and starting from 9-Thr (242 
mg, 0.55 mmol), compound 10-Thr (322 mg, 73%) was obtained as a white solid. 
Pysical data: mp: 76–78 ºC, [α]D
20 (c=1.00, CHCl3): +78.3. HRMS (ESI+) (m/z) 801.3271 [M+H]
+; calculated 
C40H53N2O13S
+: 801.3263. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.76–7.73 (m, 2H, arom), 7.64–7.59 (m, 2H, arom), 
7.40–7.35 (m, 2H, arom), 7.33–7.27 (m, 2H, arom), 5.75 (d, J = 8.7 Hz, 1H, NHAc), 5.54–5.46 (m, 2H, H1, NHFmoc), 
5.37 (s, 1H, H4), 5.04 (dd, J = 11.7, 2.7 Hz, 1H, H3), 4.71–4.82 (m, 1H, H2), 4.53 (t, J = 6.4 Hz, 1H, H5), 4.43–4.34 (m, 
2H, CH2Fmoc), 4.20–4.19 (m, 2H, Hα, CHFmoc), 4.14–4.04 (m, 2H, 2H6), 3.98 (d, J = 6.1 Hz, 1H, Hβ), 3.62–3.54 (m, 1H, 
Hδ), 3.41–3.30 (m, 1H, Hδ), 2.74–2.55 (m, 2H, 2Hζ), 2.12 (s, 3H, COCH3), 2.02–1.95 (m, 9H, 3 COCH3, NHCOCH3), 
1.89–1.78 (m, 2H, 2Hε), 1.46 (s, 9H, C(CH3)3), 1.18 (d, J = 6.2 Hz, 3H, 3Hγ).
 13C NMR (100 MHz, CDCl3) δ (ppm): 
171.0, 170.4, 170.3, 170.2, 169.8, 156.8 (6 CO), 144.0, 143.9, 141.4, 127.8, 127.1, 125.2, 120.0 (arom), 85.1 (C1), 82.1 
(C(CH3)3), 75.6 (Cβ), 68.6 (C3), 67.4 (C4, C5, Cδ), 67.2 (CH2Fmoc), 61.9 (C6), 59.1 (Cα), 48.4 (C2), 47.3 (CHFmoc), 30.2 
(Cε), 28.2 (C(CH3)3), 28.0 (Cζ), 23.3 (NHCOCH3), 20.8, 20.8 (3 COCH3), 16.4 (Cγ). 
 
N-Fmoc-S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)-L-homohomocysteine tert-butyl ester 
(12) 
THERMAL WAY: A solution of N-Fmoc-L-allylglycine tert-butyl ester 11 (100 mg, 0.25 mmol), compound 1 (157 mg, 
0.43 mmol) and AIBN (25 mg, 0.15 mmol) in CHCl3 (2.5 mL) was heated at reflux. After stirring for 3 h, another portion 
of AIBN (25 mg, 0.15 mmol) was added and the reaction was stirred for 4 h more. The reaction mixture was cooled, 
concentrated and then chromatographed on silica gel using EtOAc/CH2Cl2 (8:2) as eluent to give protected glycosyl 
amino acid 12 (140 mg, 70%)  as a white solid.  
PHOTOCHEMICAL WAY: A solution of compound 11 (142 mg, 0.36 mmol), compound 1 (156 mg, 0.43 mmol) and 
DPAP (19 mg, 0.07 mmol)  in CH2Cl2 (2.5 mL) was irradiated at λmax 365 nm. After stirring for 3 h, another portion of 
DPAP (19 mg, 0.07 mmol) was added and the reaction was stirred for an additional time (4 h). The reaction mixture was 
concentrated and the residue was chromatographed on silica gel using EtOAc/CH2Cl2 (8:2) as eluent to give protected 
glycosyl amino acid 12 (137 mg, 50%) as a white solid.  
REPAIRING TEC WAY: A solution of compound 11 (214 mg, 0.54 mmol), compound 1 (395 mg, 1.09 mmol), 
catechol (72 mg, 0.65 mmol) and BEt3 (95 µL, 0.65 mmol) in CH2Cl2 (0.72 mL) was stirred at room temperature. After 
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stirring for 1 h, another portion of BEt3 (8 µL, 0.05 mmol) was added (until complete consumption of compound 11). The 
reaction mixture was concentrated and the residue chromatographed on silica gel using EtOAc/CH2Cl2 (7:3) as eluent to 
give protected glycosyl amino acid 12 (288 mg, 70%) as a white solid. 
Physical data: mp: 59–61 ºC, [α]D
20 (c=1.00, CHCl3): +85.5. HRMS (ESI+) (m/z) 757.3012 [M+H]
+; calculated 
C38H49N2O12S
+: 757.3001. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.76–7.71 (m, 2H, arom), 7.61–7.56 (m, 2H, arom), 
7.40–7.30 (m, 2H, arom), 7.33–7.27 (m, 2H, arom), 5.80 (d, J = 8.7 Hz, 1H, NHAc), 5.54–5.48 (m, 2H, NHFmoc, H1), 
5.35 (s, 1H, H4), 5.03 (dd, J = 11.6, 2.3 Hz, 1H, H3), 4.79–4.71 (m, 1H, H2), 4.51 (t, J = 6.4 Hz, 1H, H5), 4.37 (d, J = 6.9 
Hz, 2H, CH2Fmoc), 4.29–4.18 (m, 2H, CHFmoc, Hα), 4.13–4.03 (m, 2H, H6), 2.66–2.54 (m, 2H, 2Hδ), 2.12 (s, 3H, COCH3), 
2.01–1.85 (m, 10H, 2 COCH3, NHCOCH3, Hβ), 1.78–1.59 (m, 3H, Hβ, 2Hγ), 1.46 (s, 9H, C(CH3)3).
 13C NMR (100 
MHz, CDCl3) δ (ppm): 171.4, 171.2, 170.5, 170.4, 170.2, 156.1 (6 CO), 144.0, 141.4, 127.9, 127.2, 125.2, 120.1 (arom), 
85.3 (C1), 82.6 (C(CH3)3), 68.7 (C3), 67.4, 67.4 (C4, C5), 67.1 (CH2Fmoc), 61.8 (C6), 53.6 (Cα), 48.5 (C2), 47.3 (CHFmoc), 
32.2 (Cβ), 30.9 (Cδ), 28.7 (C(CH3)3), 25.7 (Cγ), 23.5 (NHCOCH3), 20.9, 20.8 (3 COCH3). 
 
N-Fmoc-S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)-L-homocysteine tert-butyl ester (14) 
Under an inert atmosphere, a solution of compound 1 (1.21 g, 3.36 mmol) in dry DMF (6 mL) was transferred into a 
Schlenk, which contains 4 Å molecular sieves, previously activated at 280 °C for 4 h under vacuum. After stirring for 5 
min, a solution of compound 13 (500 mg, 1.12 mmol) in dry DMF (12 mL) was dropped into the Schlenk. The reaction 
was stirred for 24 h at room temperature, filtered over celite (to discard the molecular sieves) and the solvent was 
concentrated. The residue was purified by gradient column chromatography on silica gel using the following set of 
proportions: EtOAc/hexane, (1:1), (6:4), (7:3) to give protected glycosyl amino acid 14 (416 mg, 50%) as a white solid. 
Mp: 54–56 ºC, [α]D
20 (c=1.00, CHCl3): +68.2. HRMS (ESI+) (m/z) 743.2844 [M+H]
+; calculated C37H47N2O12S
+: 
743.2846. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.77–7.75 (m, 2H, arom), 7.60–7.58 (m, 2H, arom), 7.42–7.38 (m, 2H, 
arom), 7.33–7.30 (m, 2H, arom), 5.56 (d, J = 8.7 Hz, 1H, NHAc), 5.48 (d, J = 5.0 Hz, 1H, H1), 5.43 (d, J = 7.9 Hz, 1H, 
NHFmoc), 5.39–5.38 (m, 1H, H4), 5.06–5.02 (m, 1H, H3), 4.82–4.75 (m, 1H, H2), 4.56–4.53 (m, 1H, H5), 4.40 (d, J = 
6.7, 2H, CH2Fmoc), 4.35–4.31 (m, 1H, Hα), 4.22 (t, J = 6.2 Hz, 1H, CHFmoc), 4.17–4.04 (m, 2H, 2H6), 2.74–2.55 (m, 2H, 
2Hγ), 2.16–1.97 (m, 14H, 3 COCH3, NHCOCH3, 2Hβ), 1.48 (s, 9H, C(CH3)3).
 13C NMR (100 MHz, CDCl3) δ (ppm): 
171.0, 170.4, 170.3, 170.2, 167.8, 155.9 (6 CO), 143.9, 143.8, 141.3, 127.8, 127.1, 125.0, 120.0 (arom), 85.7 (C1), 82.9 
(C(CH3)3), 68.5 (C3), 67.5 (C5), 67.3 (C4), 67.0 (CH2Fmoc), 61.7 (C6), 53.6 (Cα), 48.3 (C2), 47.2 (CHFmoc), 33.5 (Cβ), 
28.0 (C(CH3)3), 27.5 (Cγ), 23.3 (NHCOCH3), 20.7, 20.7, 20.7 (3  COCH3). 
 
N-Fmoc-S-((2-acetamido-2-deoxy)-(3,4,6-tri-O-acetyl)-α-D-galactopyranosyl)-L-cysteine tert-butyl ester (16) 
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Under an inert atmosphere, a solution of compound 1 (1.01 g, 2.784 mmol) in dry DMF (6 mL) was transferred into a 
Schlenk, which contains the 4 Å molecular sieves, previously activated at 280 °C for 4 h under vacuum. After stirring for 
5 min, a solution of compound 15 (400 mg, 0.928 mmol) in dry DMF (12 mL) was dropped into the Schlenk. The reaction 
was stirred for 24 h at room temperature, filtered over celite (to discard the molecular sieves) and the solvent was 
concentrated. The residue was purified by gradient column chromatography on silica gel using the following set of 
proportions: EtOAc/hexane, (1:1), (6:4), (7:3) to give protected glycosyl amino acid 16 (330 mg, 51%) as a white solid. 
Mp: 59–61 ºC, [α]D
20 (c=1.00, CHCl3): +72.8. HRMS (ESI+) (m/z) 729.2686 [M+H]
+; calculated C36H45N2O12S
+: 
729.2688. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.77–7.75 (m, 2H, arom), 7.64–7.62 (m, 2H, arom), 7.42–7.29 (m, 4H, 
arom), 6.10 (d, J = 8.5 Hz, 1H, NHAc), 5.65 (d, J = 8.9 Hz, 1H, NHFmoc), 5.38–5.37 (m, 2H, H1, H4), 4.98–4.94 (m, 1H, 
H3), 4.85–4.78 (m, 1H, H2), 4.59–4.55 (m, 1H, Hα), 4.48–4.38 (m, 3H, H5, CH2Fmoc), 4.23–4.19 (m, 2H, H6, CHFmoc), 
4.02–3.98 (m, 1H, H6), 3.29–3.20 (m, 1H, Hβ), 3.05−2.98 (m, 1H, Hβ), 2.18 (s, 3H, COCH3), 2.01 (s, 3H, NHCOCH3), 
1.99 (s, 3H, COCH3), 1.97 (s, 3H, COCH3), 1.47 (s, 9H, C(CH3)3). 
 13C NMR (100 MHz, CDCl3) δ (ppm): 171.0, 170.5, 
170.2, 170.0, 168.8, 155.8 (6 CO), 143.9, 143.8, 141.4, 127.7, 127.1, 125.1, 120.1 (arom), 87.3 (C1), 82.9 (C(CH3)3), 68.3 
(C3), 68.2 (C5), 67.4 (C4), 66.9 (CH2Fmoc), 62.0 (C6), 54.5 (Cα), 48.4 (C2), 47.2 (CHFmoc), 36.2 (Cβ), 28.0 (C(CH3)3), 
23.3 (NHCOCH3), 20.7, 20.7, 20.6 (3 COCH3). 
 
Ala-Pro-Asp-Cys(α-S-GalNAc)-Arg-Pro-NH2 (17) 
Following SPPS methodology with Fmoc-Pro-OH (337 mg, 1 mmol), Fmoc-Arg(Pbf)-OH (649 mg, 1 mmol), Fmoc-
Cys(α-S-(AcO)3GalNAc)-OH (137 mg, 0.2 mmol), Fmoc-Asp(O
tBu)-OH (412 mg, 1 mmol), Fmoc-Pro-OH (337 mg, 1 
mmol), Fmoc-Ala-OH (311 mg, 1 mmol), peptide 17 was obtained with a 58% yield after purification by reversed phase 
HPLC and lyophilization (tR 20.7 min). HRMS (ESI+) (m/z) 860.3936 [M+H]
+; calculated C34H58N11O13S
+: 860.3938. 
1H NMR (400 MHz, H2O/D2O 9:1) δ (ppm) amide protons: 8.67 (t, J = 6.9 Hz, 1H, NHAsp), 8.40 (d, J = 7.5 Hz, 1H, 
NHCys), 8.36 (d, J = 7.4 Hz, 1H, NHArg), 8.20 (d, J = 8.2 Hz, 1H, NHCOCH3), 7.70 (s, 1H, CONH2), 7.20 (t, J = 5.3 Hz, 
1H, NHεArg), 7.00 (s, 1H, CONH2), 6.67 (br s, 2H, NH2ηArg). 
1H NMR (400 MHz, D2O) δ (ppm): 5.58 (d, J = 5.4 Hz, 
1H, H1), 4.73 (t, J = 6.7 Hz, 1H, HαAsp),4.68 (d, J = 3.9 Hz, 1H, HαArg), 4.65–4.57 (m, 1H, HαCys), 4.54–4.46 (m, 1H, 
HαPro), 4.44–4.35 (m, 3H, H2, HαPro, HαAla), 4.27–4.17 (m, 1H, H5), 4.00 (d, J = 2.9 Hz, 1H, H4), 3.85–3.59 (m, 7H, 
2HδPro, 2HδPro, 2H6, H3), 3.30–3.18 (m, 2H, 2HδArg), 3.16–2.83 (m, 4H, 2HβAsp, 2HβCys), 2.45–2.25 (m, 2H, 
HβPro, HβPro), 2.14–1.91 (m, 9H, NHCOCH3, 2HβArg, HβPro, HβPro, HγPro, HγPro), 1.82–1.60 (m, 4H, HγPro, 
HγPro, 2HγArg), 1.55 (d, J = 7.0 Hz, 3H, 3HβAla). 13C NMR (100 MHz, CDCl3) δ (ppm): 176.8, 174.6, 173.9, 173.6, 
171.9, 171.4, 171.1, 169.2 (8 CO), 156.8 (CζArg), 85.4 (C1), 71.9 (C5), 68.4 (C4), 67.6 (C3), 61.1 (C6), 60.3 (CαPro , 
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CαPro), 53.7 (CαCys), 51.1 (CαArg), 50.1 (CαAsp), 50.0 (C2), 48.0 (CαAla), 47.9 (CδPro), 47.7 (CδPro), 40.6 (CδArg), 
35.2 (CβAsp), 32.6 (CβCys), 29.6 (CβPro), 29.3 (CβPro), 27.7 (CγPro), 24.7(CγPro), 24.6 (CβArg), 24.1 (CγArg), 21.9 
(NHCOCH3), 15.1 (CβAla). 
 
Ala-Pro-Asp-hCys(α-S-GalNAc)-Arg-Pro-NH2 (18) 
Following SPPS methodology with Fmoc-Pro-OH (337 mg, 1 mmol), Fmoc-Arg(Pbf)-OH (649 mg, 1 mmol), Fmoc-
hCys(α-S-(AcO)3GalNAc)-OH (135 mg, 0.2 mmol), Fmoc-Asp(O
tBu)-OH (412 mg, 1 mmol), Fmoc-Pro-OH (337 mg, 1 
mmol), Fmoc-Ala-OH (311 mg, 1 mmol), peptide 18 was obtained with a 67% yield after purification by reversed phase 
HPLC and lyophilization (tR 20.8 min). HRMS (ESI+) (m/z) 874.4084 [M+H]
+; calculated C35H60N11O13S
+: 874.4087. 
1H NMR (400 MHz, H2O/D2O 9:1) δ (ppm) amide protons: 8.63 (d, J = 7.0 Hz, 1H, NHAsp), 8.39 (d, J = 7.6 Hz, 1H, 
NHArg), 8.27 (d, J = 7.2 Hz, 1H, NHhCys), 8.21 (d, J = 8.2 Hz, 1H, NHCOCH3), 7.71 (s, 1H, CONH2), 7.21 (t, J = 5.2 
Hz, 1H, NHεArg), 7.00 (s, 1H, CONH2), 6.67 (br s, 2H, NH2ηArg). 
1H NMR (400 MHz, D2O) δ (ppm): 5.50 (d, J = 5.4 
Hz, 1H, H1), 4.68–4.63 (m, 2H, HαAsp, HαhCys), 4.54–4.47 (m, 2H, HαPro, HαArg), 4.42–4.34 (m, 3H, H2, HαPro, 
HαAla), 4.30–4.27 (m, 1H, H5), 4.00 (s, 1H, H4), 3.89–3.64 (m, 7H, 2HδPro, 2HδPro, 2H6, H3), 3.23 (t, J = 6.7 Hz, 2H, 
2HδArg), 3.01–2.85 (m, 2H, 2HβAsp), 2.67 (t, J = 6.9 Hz, 2H, 2HγhCys), 2.39–2.28 (m, 2H, HβPro, HβPro), 2.23–1.67 
(m, 15H, HβPro, HβPro, 2HγPro, 2HγPro, 2HβhCys, 2HβArg, 2HγArg, NHCOCH3), 1.55 (d, J = 6.9 Hz, 3H, 3HβAla). 
13C NMR (100 MHz, CDCl3) δ (ppm): 175.8, 174.5, 173.8, 173.5, 172.8, 172.1, 171.3, 169.3 (8 CO), 156.8 (CζArg), 
84.8 (C1), 71.8 (C5), 68.5 (C4), 67.7 (C3), 61.2 (C6), 60.3 (CαPro, CαPro), 52.4 (CαArg), 51.2 (CαhCys), 50.1 (CαAsp), 
50.0 (C2), 48.0 (CαAla), 47.9 (CδPro), 47.7 (CδPro), 40.5 (CδArg), 35.0 (CβAsp), 31.3 (CγPro), 29.6 (CβPro), 29.4 
(CβPro), 27.4 (CγPro), 27.1 (CγhCys), 24.7 (CβArg), 24.7 (CβhCys), 24.1 (CγArg), 21.9 (NHCOCH3), 15.1 (CβAla). 
 
Ala-Pro-Asp-hhCys(α-S-GalNAc)-Arg-Pro-NH2 (19) 
Following SPPS methodology with Fmoc-Pro-OH (337 mg, 1 mmol), Fmoc-Arg(Pbf)-OH (649 mg, 1 mmol), Fmoc-
hhCys(α-S-(AcO)3GalNAc)-OH (140 mg, 0.2 mmol), Fmoc-Asp(O
tBu)-OH (412 mg, 1 mmol), Fmoc-Pro-OH (337 mg, 1 
mmol), Fmoc-Ala-OH (311 mg, 1 mmol), peptide 19 was obtained with a 59% yield after purification by reversed phase 
HPLC and lyophilization (tR 24.4 min). HRMS (ESI+) (m/z) 888.4251 [M+H]
+; calculated C36H62N11O13S
+: 888.4249. 
1H NMR (400 MHz, H2O/D2O 9:1) δ (ppm) amide protons: 8.63 (d, J = 7.0 Hz, 1H, NHAsp), 8.32 (d, J = 7.3 Hz, 1H, 
NHArg), 8.27 (d, J = 7.1 Hz, 1H, NHhhCys), 8.20 (d, J = 8.1 Hz, 1H, NHCOCH3), 7.69 (s, 1H, CONH2), 7.20 (t, J = 5.2 
Hz, 1H, NHεArg), 7.00 (s, 1H, CONH2), 6.67 (br s, 2H, NH2ηArg). 
1H NMR (400 MHz, D2O) δ (ppm): 5.49 (d, J = 5.4 
Hz, 1H, H1), 4.68–4.64 (m, 2H, HαAsp, HαArg), 4.50–4.46 (m, 1H, HαPro), 4.41–4.30 (m, 4H, H2, HαPro, HαAla, 
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HαhhCys), 4.25 (t, J = 5.9 Hz, 1H, H5), 3.98 (d, J = 2.8 Hz, 1H, H4), 3.83 (dd, J = 11.4, 3.1 Hz, 1H, H3), 3.81–3.58 (m, 
6H, 2H6, 2HδPro, 2HδPro), 3.27–3.16 (m, 2H, 2HδArg), 2.95 (dd, J = 17.0, 6.5 Hz, 1H, HβAsp), 2.85 (dd, J = 17.0, 7.1 
Hz, 1H, HβAsp), 2.70–2.55 (m, 2H, 2HδhhCys), 2.38–2.27 (m, 2H, HβPro, HβPro), 2.10–1.81 (m, 11H, NHCOCH3, 
2HβhhCys, 2HγhhCys, HβPro, HβPro, HγPro, HγPro), 1.80–1.58 (m, 6H, 2HγArg, 2HβArg, HγPro, HγPro), 1.54 (d, J = 
7.0 Hz, 3H, 3HβAla). 13C NMR (100 MHz, D2O) δ (ppm): 176.8, 174.5, 173.8, 173.5, 173.1, 172.0, 171.3, 169.2 (8 CO), 
156.7 (CζArg), 83.6 (C1), 71.7 (C5), 68.5 (C4), 67.7 (C3), 61.2 (C6), 60.3 (CαPro), 60.3 (CαPro), 53.2 (CαhhCys), 51.0 
(CαArg), 50.1 (CαAsp), 50.0 (C2), 48.0 (CαAla), 47.9 (CδPro), 47.7 (CδPro), 40.6 (CδArg), 35.1 (CβAsp), 30.0 (CγPro), 
29.6 (CβPro, CβhhCys), 29.4 (CβPro), 29.4 (CδhhCys), 27.4 (CγPro), 25.0 (CβArg), 25.0 (CγhhCys), 24.1 (CγArg), 21.9 
(NHCOCH3), 15.1 (CβAla). 
 
Ala-Pro-Asp-Ser(O-mercaptopropyl-α-S-GalNAc)-Arg-Pro-NH2 (20) 
Following SPPS methodology with Fmoc-Pro-OH (337 mg, 1 mmol), Fmoc-Arg(Pbf)-OH (649 mg, 1 mmol), Fmoc-
Ser(mercaptopropyl-α-S-(AcO)3GalNAc)-OH (146 mg, 0.2 mmol), Fmoc-Asp(O
tBu)-OH (412 mg, 1 mmol), Fmoc-Pro-
OH (337 mg, 1 mmol), Fmoc-Ala-OH (311 mg, 1 mmol), peptide 20 was obtained with a 67% yield after purification by 
reversed phase HPLC and lyophilization (tR 25.7 min). HRMS (ESI+) (m/z) 459.7210 [M+2H]
+2; calculated 
C37H65N11O14S
+2: 459.7211. 1H NMR (400 MHz, H2O/D2O 9:1) δ (ppm) amide protons: 8.60 (d, J = 6.8 Hz, 1H, 
NHAsp), 8.31–8.20 (m, 3H, NHSer, NHArg, NHCOCH3), 7.69 (s, 1H, CONH2), 7.25 (d, J = 6.8 Hz, 1H, NHεArg), 7.01 
(s, 1H, CONH2), 6.68 (br s, 2H, NH2ηArg). 
1H NMR (400 MHz, D2O) δ (ppm): 5.50 (d, J = 5.4 Hz, 1H, H1), 4.76–4.68 
(m, 2H, HαAsp, HαArg), 4.53 (t, J = 5.0 Hz, 1H, HαSer), 4.51–4.47 (m, 1H, HαPro), 4.42–4.32 (m, 3H, H2, HαPro, 
HαAla), 4.26 (t, J = 6.0 Hz, 1H, H5), 3.99 (d, J = 2.8 Hz, 1H, H4), 3.83 (dd, J = 11.4, 3.0 Hz, 1H, H3), 3.81–3.70 (m, 6H, 
2H6, HδPro, HδPro, 2HβSer), 3.69–3.55 (m, 4H, HδPro, HδPro, 2HδSer), 3.27–3.17 (m, 2H, 2HδArg), 2.98 (dd, J = 17.1, 
6.4 Hz, 1H, HβAsp), 2.89 (dd, J = 17.1, 6.9 Hz, 1H, HβAsp), 2.72–2.56 (m, 2H, HζSer), 2.39–2.26 (m, 2H, HβPro, 
HβPro), 2.11–1.80 (m, 12H, NHCOCH3, 2HβArg, 2HεSer, HβPro, HβPro, 2HγPro, HγPro), 1.79–1.59 (m, 3H, HγPro, 
2HγArg), 1.55 (d, J = 7.0 Hz, 3H, 3HβAla). 13C NMR (100 MHz, D2O) δ (ppm): 176.8, 174.5, 173.8, 173.6, 172.2, 
171.1, 170.0, 169.3 (8 CO), 156.7 (CζArg), 83.9 (C1), 71.7 (C5), 69.5 (CδSer), 69.1 (CβSer), 68.5 (C4), 67.7 (C3), 61.2 
(C6), 60.4 (CαPro), 60.4 (CαPro), 53.6 (CαSer), 51.0 (CαArg), 50.2 (C2), 50.0 (CαAsp), 48.1 (CαAla), 47.9 (CδPro), 
47.8 (CδPro), 40.6 (CδArg), 35.2 (CβAsp), 29.6 (CβPro), 29.4 (CβPro), 28.7 (CεSer), 27.7 (CγPro), 26.9 (CζSer), 24.7, 
24.6 (CβArg, CγPro), 24.0 (CγArg), 21.9 (NHCOCH3), 15.1 (CβAla). 
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Ala-Pro-Asp-Cys(S-mercaptopropyl-α-S-GalNAc)-Arg-Pro-NH2 (21) 
Following SPPS methodology with Fmoc-Pro-OH (337 mg, 1 mmol), Fmoc-Arg(Pbf)-OH (649 mg, 1 mmol), Fmoc-
Cys(mercaptopropyl-α-S-(AcO)3GalNAc)-OH (149 mg, 0.2 mmol), Fmoc-Asp(O
tBu)-OH (412 mg, 1 mmol), Fmoc-Pro-
OH (337 mg, 1 mmol), Fmoc-Ala-OH (311 mg, 1 mmol), peptide 21 was obtained with a 63% yield after purification by 
reversed phase HPLC and lyophilization (tR 30.3 min). HRMS (ESI+) (m/z) 934.4123 [M+H]
+; calculated 
C37H64N11O13S2
+: 934.4121. 1H NMR (400 MHz, H2O/D2O 9:1) δ (ppm) amide protons: 8.56 (d, J = 7.3 Hz, 1H, 
NHAsp), 8.31 (d, J = 7.5 Hz, 1H, NHArg), 8.18 (d, J = 7.4 Hz, 1H, NHCys), 8.13 (d, J = 8.0 Hz, 1H, NHCOCH3), 7.59 
(s, 1H, CONH2), 7.09 (t, J = 5.4 Hz, 1H, NHεArg), 6.91 (s, 1H, CONH2), 6.57 (br s, 1H, NH2ηArg). 
1H NMR (400 MHz, 
D2O) δ (ppm): 5.51 (d, J = 5.4 Hz, 1H, H1), 4.74–4.66 (m, 2H, HαAsp, HαArg), 4.55–4.47 (m, 2H, HαCys, HαPro), 
4.41–4.31 (m, 3H, H2, HαPro, HαAla), 4.26 (t, J = 6.0 Hz, 1H, H5), 3.99 (d, J = 2.4 Hz, 1H, H4), 3.86–3.79 (m, 2H, H3, 
HδPro), 3.77 (d, J = 6.2 Hz, 2H, 2H6), 3.75–3.69 (m, 1H, HδPro), 3.69–3.60 (m, 2H, 2HδPro), 3.26–3.18 (m, 2H, 
2HδArg), 3.02–2.94 (m, 2H, HβCys, HβAsp), 2.91–2.84 (m, 2H, HβAsp, HβCys), 2.77–2.63 (m, 4H, 2HζCys, 2HδCys), 
2.39–2.27 (m, 2H, HβPro, HβPro), 2.10–1.92 (m, 9H, NHCOCH3, 2HβArg, 2HγPro, 2HβPro), 1.91–1.82 (m, 3H, 
2HεCys, HγPro), 1.80–1.61 (m, 3H, HγPro, 2HγArg), 1.54 (d, J = 7.0 Hz, 3H, 3HβAla). 13C NMR (100 MHz, D2O) δ 
(ppm): 176.8, 174.5, 173.8, 173.5, 171.9, 171.5, 171.1, 169.3 (8 CO), 156.7 (CεArg), 83.9 (C1), 71.7 (C5), 68.5 (C4), 
67.6 (C3), 61.2 (C6), 60.4 (CαPro), 60.3 (CαPro), 52.9 (CαCys), 51.1 (CαArg), 50.2 (C2), 49.9 (CαAsp), 48.0 (CαAla), 
47.9 (CδPro), 47.7 (CδPro), 40.6 (CδArg), 35.1 (CβAsp), 32.5 (CβCys), 30.3 (CδCys), 29.6 (CβPro), 29.4 (CβPro), 29.1 
(CζCys), 28.6 (CεCys), 27.6 (CγPro), 24.7, 24.6 (CβArg, CγPro), 24.1 (CγArg), 21.9 (NHCOCH3), 15.1 (CβAla). 
 
Ala-Pro-Asp-Thr(O-mercaptopropyl-α-S-GalNAc)-Arg-Pro-NH2 (22) 
Following SPPS methodology with Fmoc-Pro-OH (337 mg, 1 mmol), Fmoc-Arg(Pbf)-OH (649 mg, 1 mmol), Fmoc-
Thr(mercaptopropyl-α-S-(AcO)3GalNAc)-OH (149 mg, 0.2 mmol), Fmoc-Asp(O
tBu)-OH (412 mg, 1 mmol), Fmoc-Pro-
OH (337 mg, 1 mmol), Fmoc-Ala-OH (311 mg, 1 mmol), glycopeptide 22 was obtained with a 62% yield after 
purification by reversed phase HPLC and lyophilization (tR 29.7 min). HRMS (ESI+) (m/z) 932.4506 [M+H]
+; calculated 
C38H66N11O14S
+: 932.4506. 1H NMR (400 MHz, H2O/D2O 9:1) δ (ppm) amide protons: 8.71 (d, J = 7.0 Hz, 1H, 
NHAsp), 8.23 (d, J = 7.9 Hz, 1H, NHCOCH3), 8.18 (d, J = 7.4 Hz, 1H, NHArg), 8.06 (d, J = 8.2 Hz, 1H, NHThr), 7.68 (s, 
1H, CONH2), 7.21 (t, J = 4.5 Hz, 1H, NHεArg), 7.01 (s, 1H, CONH2), 6.67 (br s, 2H, NH2ηArg). 
1H NMR (400 MHz, 
D2O) δ (ppm): 5.45 (d, J = 5.5 Hz, 1H, H1), 4.78–4.74 (m, 1H, HαAsp), 4.65 (dd, J = 8.1, 5.3 Hz, 1H, HαArg), 4.46 (dd, 
J = 8.1, 6.3 Hz, 1H, HαPro), 4.40–4.28 (m, 4H, H2, HαThr, HαPro, HαAla), 4.22 (t, J = 6.0 Hz, 1H, H5), 4.01–3.94 (m, 
2H, HβThr, H4), 3.79 (dd, J = 11.4, 3.1 Hz, 1H, H3), 3.76–3.55 (m, 7H, 2H6, 2HδPro, 2HδPro, HδThr), 3.46–3.38 (m, 
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1H, HδThr), 3.23–3.15 (m, 2H, 2HδArg), 2.97 (dd, J = 17.1, 7.0 Hz, 1H, HβAsp), 2.87 (dd, J = 17.1, 6.6 Hz, 1H, HβAsp), 
2.69–2.50 (m, 2H, 2HζThr), 2.36–2.22 (m, 2H, HβPro, HβPro), 2.08–1.71 (m, 13H, NHCOCH3, 2HβArg, 2HεThr, 
HβPro, HβPro, 2HγPro, 2HγPro), 1.70–1.57 (m, 2H, 2HγArg), 1.51 (d, J = 7.0 Hz, 3H, 3HβAla), 1.13 (d, J = 6.3 Hz, 3H, 
3HγThr). 13C NMR (100 MHz, D2O) δ (ppm): 176.7, 174.5, 173.8, 173.5, 172.5, 171.2, 171.1, 169.2 (8 CO), 156.7 
(CζArg), 83.9 (C1), 74.8 (CβThr), 71.7 (C5), 68.4 (C4), 67.6 (C3), 67.4 (CδThr), 61.1 (C6), 60.2 (CαPro, CαPro), 57.8 
(CαThr), 51.1 (CαArg), 50.2 (C2), 49.9 (CαAsp), 48.0 (CαAla), 47.9 (CδPro), 47.6 (CδPro), 40.6 (CδArg), 35.0 
(CβAsp), 29.6 (CβPro), 29.4 (CβPro), 29.0 (CεThr), 27.6 (CγPro), 26.9 (CζThr), 24.7, 24.6 (CβArg, CγPro), 24.1 
(CγArg), 21.9 (NHCOCH3), 15.7 (CγThr), 15.0 (CβAla). 
2D NMR experiments. Spectra were assigned using COSY and HSQC experiments. NOESY experiments were recorded 
on a 400 MHz spectrometer at 298 K and pH 5.5 in H2O/D2O (9:1). The experiments were conducted by using phase- 
sensitive ge-2D NOESY with WATERGATE for H2O/D2O (9:1) spectra. Distances involving NH protons were semi-
quantitatively determined by integrating the volume of the corresponding cross-peaks. The number of scans used was 16 
and the mixing time was 500 ms. 
Molecular dynamics (MD) simulations with time averaged restraints (MD-tar). The simulations were carried out with 
AMBER 12 package54 with ff14SB55, GAFF56 and GLYCAM06j57 force fields. The parameters and charges for the 
unnatural amino acids were generated with the antechamber module of AMBER 12, using GAFF force field and AM1-
BCC method for charges.58 Prior to MD-tar productive simulations, we performed an equilibration protocol consisting of 
an initial minimization of the water box of 5000 steps, followed by a 2500-step minimization of the whole system. Then, 
the TIP3P water59 box was heated at constant volume until 298 K using a time constant for the heat bath coupling of 1 ps. 
The equilibration finished with 200 ps of MD simulation without restraints, at a constant pressure of 1 bar and turning on 
the Langevin temperature scaling with a collision frequency of 1 ps. Furthermore, non-bonded interactions were cut-off at 
8.0 Å and updated every 25 steps. Periodic boundary conditions and the Particle Mesh Ewald method60 were turned on in 
every step of the equilibration protocol to evaluate the long-range electrostatic forces, using a grid spacing of 
approximately 1 Å. The NOE-derived distances shown in Figure 2 and in the Supporting Information were imposed as 
time-averaged constraint, applying an r−6 averaging. The equilibrium distance range was set to rexp − 0.2 Å ≤ rexp ≤ rexp + 
0.2 Å. Trajectories were run at 298 K, with a decay constant of 2000 ps and a time step of 1 fs. The force constants rk2 and 
rk3 used in each case were 10 kcal·mol
−1·Å−2. The overall simulation length for the simulations was 20 ns. The coordinates 
were saved each 1 ps, obtaining MD trajectories of 20000 frames each. A convergence within the equilibrium distance 
range was obtained in the simulations. 
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Molecular dynamics (MD) simulations on the complex SM3:22. The crystal structure of glycopeptides 22 in complex 
with scFv-SM3 (PDB id: 5fxc) was used as starting coordinates. The structure was conveniently modified to contain the 
missing linker as well as the GalNAc unit for the glycopeptide. The complex was then immersed in a water box with a 10 
Å buffer of TIP3P water molecules. A two-stage geometry optimization approach was performed. The first stage 
minimizes only the positions of solvent molecules and the second stage is an unrestrained minimization of all the atoms in 
the simulation cell. The systems were then gently heated by incrementing the temperature from 0 to 300 K under a 
constant pressure of 1 atm and periodic boundary conditions. Harmonic restraints of 30 kcal·mol-1 were applied to the 
solute, and the Andersen temperature-coupling scheme was used to control and equalize the temperature. The time step 
was kept at 1 fs during the heating stages, allowing potential inhomogeneities to self-adjust. Long-range electrostatic 
effects were modelled using the particle-mesh-Ewald method. An 8 Å cut-off was applied to Lennard-Jones and 
electrostatic interactions. Each system was equilibrated for 2 ns with a 2 fs time step at a constant volume and temperature 
of 300 K. Production trajectories were then run for additional 100 ns under the same simulation conditions. 
Crystallization. Expression and purification of scFv-SM3 has been described previously by us.53 Crystals were grown by 
sitting drop diffusion at 18 ºC. The drops were prepared by mixing 0.5 µL of protein solution, containing 15 mg/mL of 
scFv-SM3 and 10 mM of glycopeptide 22 with 0.5 µL of the mother liquor. Crystals of scFv-SM3 with the peptide above 
were grown in 20% PEG 3350, 0.2 M disodium hydrogen phosphate. The crystals were cryoprotected in mother liquor 
containing 15% ethylenglycol and frozen in a nitrogen gas stream cooled to 100 K. 
Structure determination and refinement. The data was processed and scaled using the XDS package61 and 
CCP4software,62  relevant statistics are given in Supplementary Table S1. The crystal structures were solved by molecular 
replacement with Phaser62 and using the PDB entry 1SM3 as the template. Initial phases were further improved by cycles 
of manual model building in Coot63 and refinement with REFMAC5.64 The final models were validated with 
PROCHECK,65 model statistics are given in the Supporting Information. Coordinates and structure factors have been 
deposited in the Worldwide Protein Data Bank (wwPDB). PDB id: 5fxc 
 
Supporting Information 
2D NOESY spectra of the neoglycopeptides, conformational analysis details, NMR spectra for all 
new compounds, CD spectra, HPLC chromatograms and X-ray structure details. This material is 
available free of charge via the Internet at http://pubs.acs.org. 
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